Analysis of Factors Influencing the Prognosis of Neoadjuvant Chemotherapy for Breast Cancer with Peripheral Blood Inflammatory Markers
1 Department surgery six, the first hospital of Handan city, Hebei, China
2 Department of radiology, the first hospital of Handan city, Hebei, China
3 Department of ultrasound, the first hospital of Handan city, Hebei, China
4 Department of neurology, the first hospital of handan city, Hebei, China
Cancer Genetics and Epigenetics, 2020, Vol. 8, No. 1 doi: 10.5376/cge.2020.08.0001
Received: 27 Oct., 2020 Accepted: 18 Nov., 2020 Published: 27 Nov., 2020
© 2020 BioPublisher Publishing Platform
This is an open access article published under the terms of the Creative Commons Attribution License
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Preferred citation for this article:
Liu S.H., Zhang X., Hu G.Q., and Cui R.N., 2020, Analysis of factors influencing the prognosis of neoadjuvant chemotherapy for breast cancer with peripheral blood inflammatory markers, Cancer Genetics and Epigenetics, 8(1): 1-8 (doi: 10.5376/cge.2020.08.0001)
To explore the factors influencing the prognosis of neoadjuvant chemotherapy for breast cancer. From January 2014 to January 2017 123 breast cancer patients receiving neoadjuvant chemotherapy (NAC) were selected, establish the optimal threshold value of peripheral blood inflammation indicators, patients were divided into high and low groups according to the optimal threshold, contrast different peripheral blood inflammation indexes with pathological complete remission (pCR) after chemotherapy, relationship between disease-free survival (DFS). Patients were divided into two groups with high and low ratios according to the critical values of neutrophil/lymphocyte ratio (NLR) 2.34 and PLR critical value 130.21, the pCR rate of patients with low NLR and PLR group was significantly higher than that of patients with high NLR and high PLR group (P=0.001), patients with high NLR had shorter DFS than those with low NLR (P=0.001), patients with high PLR had shorter DFS than those with low PLR (P=0.001). In patients without pCR after NAC, the DFS of patients in the high NLR group was worse than that in the low NLR group, DFS of patients in the high NLR group were worse than those in the low NLR group, DFS of patients with high PLR group was also worse than that of patients with low PLR group (All P<0.05). Multivariate analysis showed that high PLR and KI-67 were the factors that affected the poor prognosis of breast cancer patients who had received NAC, high NLR was not an independent prognostic factor. High levels of NLR and PLR in peripheral blood before NAC predict poor prognosis in breast cancer patients, Ki-67 and PLR are independent risk factors.
Breast cancer; Peripheral inflammatory markers; Neoadjuvant chemotherapy; Pathological complete remission; Disease-free survival